BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004 (Second Quarter of Fiscal Year 2004)
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 12% in Q2 2004 and 13% for the six-month period compared to the prior year. Organic growth (excluding foreign currency) was approximately 6% for both periods.
• Segment Performance:
  • Medical: Revenues up 13% (Q2) driven by safety-engineered devices, diabetes products, and prefillable drug delivery devices.
  • Diagnostics: Revenues up 7% (Q2), supported by safety-engineered devices and BD ProbeTec ET platforms.
  • Biosciences: Revenues up 17% (Q2), driven by the BD FACSAria cell sorter and flow cytometry reagents.
• Profitability: Operating income increased 18% in Q2. Gross margins improved due to a favorable product mix (higher margin safety-engineered products) and benefits from a 2002 restructuring plan.
• Unusual Items: The six-month period included a pre-tax charge of $45.0 million related to Blood Glucose Monitoring (BGM) products. This included a $6.5 million reserve for a voluntary product recall and a $29.8 million write-off of inventory, plus an $8.7 million write-off of assets related to discontinuing the BD Latitude system in the U.S.
• Liquidity: Net cash provided by operating activities surged to $528 million for the six months ended March 31, 2004, compared to $293 million in the prior year (which included a $100 million pension contribution).

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects fiscal 2004 capital spending to be between $275 million and $300 million.
• Dividends: Quarterly dividend declared at $0.15 per share.
• Share Repurchases: The company repurchased over 2 million shares for $175 million in the first six months. As of March 31, 2004, authorization remained to repurchase an additional 9.7 million shares.
• Pension Funding: The company anticipates a discretionary contribution of $18 million to the U.S. pension plan in the third quarter of 2004.
• Risks and Contingencies:
  • Legal Proceedings: BD is involved in various litigation, including product liability and patent disputes (e.g., Retractable Technologies, Inc. vs. BD). Management believes claims are without merit but notes that unfavorable outcomes could have a material adverse effect.
  • Product Recalls: Ongoing management of the BGM test strip recall and associated inventory write-offs.
  • Market Risks: Exposure to foreign currency fluctuations, healthcare cost containment initiatives, and competitive pressures.

Investor Verification Checklist

• BGM Charge Impact: Verify the full extent of the $45 million pre-tax charge on Q1 2004 results and the status of the voluntary product recall.
• Organic Growth Rates: Confirm the distinction between reported revenue growth (12-13%) and constant currency growth (~6%) to assess true operational performance.
• Debt-to-Capital Ratio: Note the reduction in debt-to-capitalization to 26.8% from 30.4% and review the terms of the $900 million syndicated credit facilities.
• Segment Mix: Analyze the shift in revenue mix toward higher-margin safety-engineered devices and the BD FACSAria cell sorter.
• Legal Exposure: Monitor the status of the Retractable Technologies litigation and the Cardozo class action regarding the BD ProbeTec ET instrument.